Trial Profile

A pivotal phase II trial of Lasmecabtagene timgedleucel in B-cell lymphoblastic leukaemia lymphoma

Status: Planning

Phase of Trial: Phase II

Latest Information Update: 25 Nov 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Lasmecabtagene timgedleucel (Primary)
Indications Precursor B-cell lymphoblastic leukaemia-lymphoma
Focus Registrational; Therapeutic Use

Most Recent Events

17 Oct 2025 Accoridng to a cellectis media release, the company anticipates submitting a Biologics License Application (BLA) in 2028.
17 Oct 2025 Accoridng to a cellectis media release, first patient in pivotal Phase 2 is expected to be enrolled in Q4 2025.
17 Oct 2025 Accoridng to a cellectis media release, company hosted an R&D Day today and unveiled the design of this pivotal Phase 2 study.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com